Patent Application
20090306142
This invention relates to methods and compositions suitable for controlling fungal plant pathogens that are resistant to Qo inhibitors.
Qo inhibitor fungicides are conventionally used to control a number of fungal pathogens in crops. Qo inhibitors typically work by inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria. Said oxidation center is located on the outer side of the inner mitochrondrial membrane. A prime example of the use of Qo inhibitors includes the use of, for example, strobilurins on wheat for the control of Septoria tritici (Bayer code: SEPTTR, also known as Mycosphaerella graminicola), which is the cause of wheat leaf blotch. Unfortunately, widespread use of such Qo inhibitors has resulted in the selection of mutant pathogens, containing a single amino acid residue substitution in their cytochrome bc1 complex, that are resistant to Qo inhibitors. See, for example, Lucas, J., “Resistance to QoI fungicides: implications for cereal disease management in Europe”, Pesticide Outlook (2003), 14(6), 268-70 (which is expressly incorporated by reference herein) and Fraaije, B. A. et al., “Role of ascospores in further spread of QoI-resistant cytochrome b alleles (G143A) in field populations of Mycosphaerella graminicola”, Phytopathology (2005), 95(8), 933-41 (which is expressly incorporated by reference herein). Thus, new methods and compositions are desirable for controlling pathogen induced diseases in crops comprising plants subjected to pathogens that are resistant to Qo inhibitors.
Fortunately, the present invention provides new methods and compositions of controlling a pathogen induced disease in a plant where the pathogen is resistant to a Qo inhibitor. The inventive methods typically comprise contacting a plant at risk of being diseased from a pathogen that is resistant to a Qo inhibitor with a composition comprising an effective amount of a Qi inhibitor. Qi inhibitors typically work by inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria, the said oxidation center being located on the inner side of the inner mitochrondrial membrane. Suitable Qi inhibitors include those selected from the group consisting of antimycins A and their synthetic mimics, such as the N-formylaminosalicylamides (FSAs) described in WO 9927783, the naturally occurring picolinamide UK2A as described in the Journal of Antibiotics, Issue 49(7), pages 639-643, 1996, (the disclosure of which is expressly incorporated by reference herein), synthetic and semisynthetic picolinamides such as those described in WO 0114339 and WO 0105769, and prodrugs, racemic mixtures, oxides, addition salts, metal or metalloid complexes, and derivatives thereof. In another embodiment, a suitable method of controlling a pathogen induced disease in a crop comprises first identifying one or more plants in the crop that are at risk of being diseased from a pathogen resistant to a Qo inhibitor and then contacting the crop with a composition comprising an effective amount of a Qi inhibitor. Suitable compositions for controlling a pathogen induced disease in a crop comprising one or more plants at risk of being diseased from a mixed population of pathogens resistant to a Qo inhibitor and pathogens sensitive to a Qo inhibitor include compositions comprising an effective amount of a Qo inhibitor and an effective amount of a Qi inhibitor.
“Composition,” as used herein, includes a mixture of materials which comprise the composition, as well as reaction products and decomposition products formed from the ingredients or materials of the composition.
“Qo inhibitor,” as used herein, includes any substance that is capable of diminishing and/or inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria. The oxidation center is typically located on the outer side of the inner mitochrondrial membrane.
“Pathogen induced disease,” as used herein, includes any abnormal condition that damages a plant and reduces its productivity or usefulness to man wherein said condition is caused by a pathogen. Typical symptoms may include visible abnormalities such as wilts, rots, and other types of tissue death, stunting, excessive growth, or abnormal color.
“Qi inhibitor,” as used herein, includes any substance that is capable of diminishing and/or inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria. The oxidation center is typically located on the inner side of the inner mitochrondrial membrane.
The present invention relates to methods of controlling a pathogen induced disease or diseases in one or more plants. The processes of the present invention are often effective in controlling said diseases in plants that are susceptible to a fungal pathogen that is at least partially resistant to a Qo inhibitor. It is not particularly important how said plant pathogen developed the at least partial resistance to Qo inhibitors but often the resistance is due to a mutation as described in Pest Management Science, Issue 58(7), pages 649-662, 2002, the disclosure of which is expressly incorporated by reference herein. For example, in the case of Septoria tritici (SEPTTR) which causes wheat leaf blotch, a G143A mutation, in which a glycine at position 143 of the amino acid sequence of the cytochrome b is replaced with an alanine, may render the SEPTTR at least partially resistant to a conventional Qo inhibitor. Other such mutations in specific plant pathogens include, for example, an F129L mutation in which a phenylalanine at position 129 is replaced with a leucine.
The inventive methods comprise contacting a plant at risk of being diseased from a pathogen that is resistant to a Qo inhibitor with a composition comprising an effective amount of a Qi inhibitor. Plants at risk of being diseased from a pathogen that is resistant to a Qo inhibitor may be identified by observing a diminished ability to control the pathogen when a Qo inhibitor is employed. Alternatively, Qo inhibitor-resistant pathogens may be identified by testing for a genetic mutation that affects binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria wherein the oxidation center is located on the outer side of the inner mitochrondrial membrane. Such a test might consist of extracting DNA from the isolated pathogen and analyzing for specific site mutations such as the G143A or F129L etc, using real time PCR techniques & gene sequencing techniques.
While not wishing to be bound by any theory it is believed that a Qi inhibitor may control or assist in controlling a Qo resistant fungal pathogen by diminishing and/or inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria. Unlike Qo inhibitors, however, the oxidation center of the cytochrome bc1 complex to which Qi inhibitors bind is typically located on the inner side of the inner mitochrondrial membrane. In this manner, the fungal pathogen is controlled or eliminated.
Useful Qi inhibitors may vary depending upon the type of plant, the fungal pathogen and environmental conditions. Typical Qi inhibitors are selected from the group consisting of antimycins A and their synthetic mimics, such as the N-formylaminosalicylamides (FSAs), the naturally occurring picolinamide UK2A, synthetic and semisynthetic picolinamides, and prodrugs, racemic mixtures, oxides, addition salts, metal or metalloid complexes, and derivatives thereof. The aforementioned Qi inhibitors have been found to be useful in controlling pathogens such as those selected from the group consisting of basidomycetes, ascomycetes, and oomycetes. More specifically, the pathogen to be controlled may be one of the group consisting of, but not limited to, Alternaria alternata, Blumeria graminis, Pyricularia oryzae (also known as Magnaporthe grisea), Septoria tritici (also known as Mycosphaerella graminicola), Mycosphaerella fijiensis, Venturia inaequalis, Pyrenophora teres, Pyrenophora tritici repentis and Plasmopara viticola. The inventive process has been found particularly effective in controlling a pathogen induced disease caused by Septora tritici in wheat.
The exact amount of Qi inhibitor to be employed often depends upon, for example, the specific active ingredient being applied, the particular action desired, the type, number and growth stage of the plants, the fungal pathogen to be controlled, application conditions and whether delivery is targeting foliage, seeds or soil in which the plants are growing. Thus all Qi inhibitor fungicides, and formulations containing the same, may not be equally effective at similar concentrations or against the same pathogens.
Typically, a plant in need of fungal protection, control or elimination is contacted with an amount of from about 0.1 to about 2500, preferably from about 1 to about 750 ppm of a Qi inhibitor. The contacting may be in any effective manner. For example, any exposed part of the plant, e.g., leaves or stems may be sprayed with the Qi inhibitor. Similarly, the Qi inhibitor may be applied in a manner such that the roots, seeds, or one or more other unexposed parts of the plant take up the Qi inhibitor such that it controls or eliminates the fungal pathogen. As a foliar fungicide treatment, the exact dilution and rate of application will depend upon the type of equipment employed, the frequency of application desired and diseases to be controlled, but the effective amount of a Qi inhibitor fungicide is usually from about 0.05 to about 2.5, and preferably from about 0.075 to about 0.5 kg per hectare.
The compositions comprising an effective amount of Qi inhibitor may be mixed with one or more other active or inert ingredients. Preferable other active ingredients may include a Qo inhibitor, such as azoxystrobin, pyraclostrobin, fluoxastrobin, trifloxystrobin or picoxystrobin, dimoxystrobin, metominostrobin, orysastrobin, kresoxim-methyl, enestrobin, famoxadone, fenamidone, pyribencarb, an azole such as epoxiconazole, prothioconazole, myclobutanil, tebuconazole, propiconazole, cyproconazole or fenbuconazole or a METII site inhibitor such as boscalid, penthiopyrad, bixafen, isopyrazam, sedaxane, fluopyram, or thifluzamide or combinations thereof. By mixing the Qi inhibitor with a Qo inhibitor, the composition may control mixed populations comprising fungal pathogens that are mutated to be Qo resistant, as well as fungal pathogens that are unmutated and are susceptible to being controlled by Qo inhibitors. Other active ingredients that may be included with an effective amount of Qi inhibitor with or without a Qo inhibitor or fungicide from a different mode of action class, include compounds such as insectides and weed control agents.
As described above, the present invention also pertains to composition suitable for controlling a pathogen induced disease in a crop comprising one or more plants at risk of being diseased from a pathogen resistant to a Qo inhibitor. Said compositions typically comprise an effective amount of a Qo inhibitor and an effective amount of a Qi inhibitor.
The naturally-occurring picolinamide UK2A, its profungicide derivative Compound 1, and 3 other Qi inhibitors—antimycin A, Compound 2 (a member of the N-formylaminosalicylamide (FSA) series), and Compound 3 (a member of a series of synthetic picolinamide mimics of UK2A), were tested for in vitro fungitoxicity towards SEPTTR field isolates LARS 15 and R2004-6 in a microtiter plate assay (Table 1). The Qo inhibitors azoxystrobin, kresoxim-methyl and famoxadone were included as standards. LARS 15 is sensitive to strobilurins, whereas R2004-6 contains the G143A mutation in cytochrome b which confers resistance to strobilurins.
The Qo inhibitors were highly active against the LARS 15 strain but showed little or no activity against the QoI-resistant strain R2004-6. In contrast, UK-2A, Compound 1 and the other Qi inhibitors were highly active against both strains and in most cases showed slightly higher activity towards the strobilurin-resistant R2004-6 strain.
The UK-2A prodrug Compound 1 was used to demonstrate that a QiI fungicide can effectively control a wide range of QoI-resistant SEPTTR isolates obtained from field samples of wheat.
A panel of 31 SEPTTR isolates was used in in vitro fungitoxicity experiments. Most of the used isolates were isolated from wheat in the UK from 2001 to 2005. Table 2 lists mean EC50 values +/−SD for Compound 1 for the 17 QoI-sensitive isolates (‘WT’) and 14 QoI-resistant isolates (‘G143A’) in comparison to azoxystrobin and epoxiconazole. The results listed in Table 2 show that, on average, the Qo inhibitor azoxystrobin controls QoI-sensitive isolates 160 fold better than QoI-resistant isolates. Also the azole, epoxiconazole, was 1.7-fold less active against QoI-resistant isolates. On the other hand, the Qi inhibitor Compound 1 was 1.7-fold more active against QoI-resistant isolates.
In-planta testing was performed on the second attached leaf of 16 day old wheat cultivar Riband, highly susceptible to SEPTTR. Wheat leaves were sprayed with a dilution series of Compound 1 (as an SC formulation) or the azoxystrobin-containing fungicide Amistar. The next day, treated leaves were inoculated with either the QoI-sensitive isolates (S27 or Lars 15-03) or the QoI-resistant isolates (G3-03 or TwistB-02). Visual inspection 21 days after inoculation revealed Amistar control of S27 and Lars 15-03 at 0.9 ppm and 2.8 ppm, respectively. No control was evident for G3-03 and TwistB-02 at 25 ppm.
Breaking rates for control of the QoI-sensitive isolates S27 and Lars 15-03 with compound 1 were 0.3 ppm and 2.8 ppm, respectively. The QoI-resistant isolates G3-03 and TwistB-02 were controlled at 0.9 ppm and 0.3 ppm.
Table 3 summarizes the results for 5 QoI-sensitive and 6 QoI-resistant strains. Amistar (azoxystrobin) control was evident for QoI-sensitive isolates with breaking rates ranging from 0.1 ppm to 8.3 ppm. Amistar did not control any of the tested QoI-resistant isolates. Even at the highest rate used (25 ppm) all leaves were infected with SEPTTR. On the other hand, the SC formulation of Compound 1, controlled both QoI-sensitive and QoI-resistant isolates with high efficacy and breaking rates ranged from 0.3 ppm to 0.9 ppm.
While the invention has been described with respect to a limited number of embodiments, the specific features of one embodiment should not be attributed to other embodiments of the invention. No single embodiment is representative of all aspects of the invention. In some embodiments, the compositions or methods may include numerous compounds or steps not mentioned herein. In other embodiments, the compositions or methods do not include, or are substantially free of, any compounds or steps not enumerated herein. Variations and modifications from the described embodiments exist. Finally, any number disclosed herein should be construed to mean approximate, regardless of whether the word “about” or “approximately” is used in describing the number. The appended embodiments and claims intend to cover all those modifications and variations as falling within the scope of the invention.
This application claims the benefit of U.S. Provisional Patent Application No. 61/130,431, filed on May 30, 2008, which is expressly incorporated by reference herein.
| Number | Date | Country | |
|---|---|---|---|
| 61130431 | May 2008 | US |
